Terrance McGuire Biography and Net Worth

Director of Invivyd


Terrance McGuire has served as a member of our Board since October 2020. Mr. McGuire was a co-founder and is currently a general partner of Polaris Partners. He currently serves on the boards of directors of Seer, Inc., a publicly-traded life sciences company focused on capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease, and Tectonic Therapeutic, Inc., a publicly traded biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-Protein Coupled Receptors. Mr. McGuire also serves on the board of directors of several private companies, including Adimab, LLC. Mr. McGuire previously served on the boards of directors of Alector, Inc., Acceleron Pharma, Inc., Akamai Technologies, Inc., Cubist, Inc., Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire is the former chairman of the National Venture Capital Association and a current member of the board of advisors of the Thayer School of Engineering at Dartmouth College. He is a member of the boards of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire is also on the Scientific Advisory Board of the Brigham and Women's Hospital. Mr. McGuire holds a B.S. in physics and economics from Hobart College, an M.S. in engineering from the Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.

What is Terrance McGuire's net worth?

The estimated net worth of Terrance McGuire is at least $5.41 million as of December 30th, 2024. Mr. McGuire owns 3,170,231 shares of Invivyd stock worth more than $5,405,244 as of April 10th. This net worth approximation does not reflect any other assets that Mr. McGuire may own. Learn More about Terrance McGuire's net worth.

How do I contact Terrance McGuire?

The corporate mailing address for Mr. McGuire and other Invivyd executives is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. Invivyd can also be reached via phone at 781-819-0080 and via email at [email protected]. Learn More on Terrance McGuire's contact information.

Has Terrance McGuire been buying or selling shares of Invivyd?

Terrance McGuire has not been actively trading shares of Invivyd during the past quarter. Most recently, Terrance Mcguire sold 86,545 shares of the business's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $0.48, for a transaction totalling $41,541.60. Following the completion of the sale, the director now directly owns 3,170,231 shares of the company's stock, valued at $1,521,710.88. Learn More on Terrance McGuire's trading history.

Who are Invivyd's active insiders?

Invivyd's insider roster includes Robert Allen, III (Chief Scientific Officer), William Duke (Chief Financial Officer), Julie Green (Chief Human Resources Officer), Timothy Lee (Chief Commercial Officer), and Terrance McGuire (Director). Learn More on Invivyd's active insiders.

Are insiders buying or selling shares of Invivyd?

In the last twelve months, Invivyd insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $125,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 504,826 shares worth more than $521,748.82. The most recent insider tranaction occured on February, 18th when insider Robert D Allen III sold 19,392 shares worth more than $30,639.36. Insiders at Invivyd own 25.4% of the company. Learn More about insider trades at Invivyd.

Information on this page was last updated on 2/18/2026.

Terrance McGuire Insider Trading History at Invivyd

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/30/2024Sell86,545$0.48$41,541.603,170,231View SEC Filing Icon  
12/26/2024Sell83,817$0.54$45,261.183,340,520View SEC Filing Icon  
12/23/2024Sell75,776$0.45$34,099.203,492,498View SEC Filing Icon  
12/20/2024Sell119,805$0.42$50,318.103,568,274View SEC Filing Icon  
12/18/2024Sell74,764$0.47$35,139.083,840,146View SEC Filing Icon  
12/16/2024Sell65,359$0.47$30,718.734,012,320View SEC Filing Icon  
12/11/2024Sell160,400$0.59$94,636.004,202,679View SEC Filing Icon  
12/9/2024Sell150,000$0.61$91,500.004,538,079View SEC Filing Icon  
5/29/2024Sell112,381$1.66$186,552.464,688,079View SEC Filing Icon  
See Full Table

Terrance McGuire Buying and Selling Activity at Invivyd

This chart shows Terrance Mcguire's buying and selling at Invivyd by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Invivyd Company Overview

Invivyd logo
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $1.77
Low: $1.62
High: $1.77

50 Day Range

MA: $1.59
Low: $1.19
High: $1.90

2 Week Range

Now: $1.77
Low: $0.46
High: $3.07

Volume

8,779,937 shs

Average Volume

3,074,031 shs

Market Capitalization

$499.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73